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To assess the contributions of Tyr-55, Met-l 10 and His-217 in porcine kidney D-amino acid oxidase (EC 1.4.3.3, DAO) 
to its catalytic function, we constructed three mutant cDNAs coding for the enzymes possessing Phe-55, Leu-110 and 
Leu-217 by site-specific mutagenesis. The mutant and wild type cDNAs could be expressed in vitro with similar efficiency. 
The three mutant enzymes thus synthesized showed catalytic activities comparable to that of the wild type oxidase. It 
is concluded that Tyr-55, Met-l 10 and His-217 are not directly involved in the catalytic function. 
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1. INTRODUCTION 
D-amino acid oxidase (EC 1.4.3.3, DAO) is a 
flavoenzyme that catalyzes the oxidative deamina- 
tion of D-amino acids. Although extensive studies 
have been made, its reaction mechanism is not yet 
fully understood. Recent chemical modification 
studies, coupled with the determination of the 
primary structure of porcine kidney DA0 [ 11, have 
shown that modifications of Tyr-224, Tyr-228 and 
His-307 [l], Tyr-55 and Lys-204 [1,2], His-217 
[1,3], and Met-l 10 [4] all result in abolishment or 
drastic decreases of the enzyme activity. However, 
in view of the difficulty associated with specific 
and complete modification of a single amino acid 
residue in a protein, these observations provide on- 
ly limited information concerning the roles of these 
residues in the catalytic mechanism. We have 
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recently isolated a full-length cDNA clone for por- 
cine kidney DA0 and determined its nucleotide se- 
quence [5]. We have also established an in vitro 
system for the synthesis of functionally active 
DA0 with the cloned cDNA as template [6]. In this 
study we attempted to confirm the results of the 
chemical modification studies by constructing mu- 
tant cDNAs by site-specific mutagenesis and by ex- 
pressing them in vitro. We report here that 
replacement of Tyr-55 with Phe, Met-110 with 
Leu, and His-217 with Leu (all in porcine DAO) 
did not affect the enzyme activity. 
2. MATERIALS AND METHODS 
2.1. Materials 
[y-32P]ATP (3000-4000 Ci/mmol), [a-“P]dCTP (410 Ci/ 
mmol), the oligonucleotide-directed mutagenesis system and the 
rabbit reticulocyte lysate were obtained from Amersham; the 
Riboprobe in vitro transcription system (pSP64 DNA, SP6 
RNA polymerase and RNasin) was from Promega Biotech; 
Ml3mpl9 replicate form DNA from Takara Shuzo Co.; 
agarose type I from Sigma; restriction endonucleases and 
sequencing reagents were from Toyobo Co.; nitrocellulose 
filters from Advantec and Schleicher & Schuell; and 
guanylyltransferase was from Bethesda Research Laboratories. 
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2.2. Site-specific mutagenesis 
A 1.34 kbp cDNA for porcine DA0 was cut out of the DA0 
cDNA clone IS] with SafI and Pvull and subcloned into the 
SalI-ha1 site of the replicative form DNA of M13mp19. This 
was used to transform E. coli JM103 cells, and the single- 
stranded DNA was purified from selected transformants, and 
used for in vitro mutagenesis. Three mutagenic primers design- 
ed for desired point mutations (table 1) were synthesized by the 
phosphoramidite method in an automated DNA synthesizer 
(Applied Biosystems, Model 380A) and purified by high- 
performance liquid chromatography on a reverse-phase (c18) 
column. The cDNAs for mutant DAOs were constructed by the 
single-primer method of site-specific mutagenesis [7]. The 
mutated cDNAs were used directly to transform competent E. 
coli JM109 cells. 
2.3. Screening of mutant cDNA 
The oligodeoxynucleotides encoding mutant DAOs were 
radiolabeled with [y-3ZP]ATP and then used for plaque 
hybridization [8] to select mutant phage DNAs. Plaques ex- 
hibiting positive hybridization signals were subjected to sequen- 
cing by the dideoxy method [9] to verify that the desired 
mutations had taken place. Three oligodeoxynucleotides con- 
taining the sequences complementary to those of DA0 cDNA 
(5 ‘-CCAGTTCGCCTCCTGTG-3 ’ , 5 ‘-AGTTCTCTGGGAG- 
TCAG-3’ and 5’-TCCAAGTGTCACTGCCTG-3’) were used 
as sequence primers to detect the Phe-55, Leu-110 and Leu-217 
mutants. 
2.4. Transcription and translation in vitro 
The mutant DA0 cDNAs were cut out of the phage vector 
with S&J and EcoRl and ligated to the same site in the 
polylinker region of pSP64 [IO] and the resultant recombinants 
were used to transform E. co/i JM109 cells as described 
previously [6]. The plasmids containing the mutant cDNA in- 
serts were linearized with EcoRI. 5 gg each of the linearized 
template was transcribed with SP6 RNA polymerase. A 
5’-terminal cap structure was added to the RNAs thus syn- 
thesized with the aid of guanylyltransferase. Translation of the 
capped RNAs was conducted in a reticulocyte lysate cell-free 
system as described [6,11]. 
2.5. Western blot analysis 
Western blot analysis was used to analyze the translation 
products as described by Burnette [12]. The products were 
transferred electrophoretically from an SDS-polyacrylamide gel 
to a nitrocellulose filter and incubated with polyclonal an- 
tiserum raised in a rabbit against purified porcine DA0 (6,l I] 
at lOOO-fold dilution. The immune complexes were 
radiographically visualized through binding of [‘2sI]protein A. 
2.6. Enzyme assay 
DA0 activity was assayed by determining the production of 
pyruvate from D-alanine. Pyruvate production was monitored 
by measuring the rate of decrease in the absorbance at 340 nm 
in a coupled system containing lactate dehydrogenase. The 
assay mixture contained 50pM FAD, 5.9 units/ml of lactate 
Table 1 
Oligonucleotide-directed mutagenesis of D-amino acid oxidase 
Desired mutation DNA sequencea 
55 
Trp Gln Pro Tyr Thr Ser Glu 
Tyr-55 (wild type) 5’. . . . TGG CAG CCC TAC ACC TCT GAG . . . .3’ 
* 
Phe-55 (mutant) 5’....................TTC....................3’ 
(Phe) 
Mutagenic primer 3 ’ -C GTC GGG AAG TGG AGA C-5 ’ 
110 
Trp Lys Asp Met Val Leu Gly 
Met-110 (wild type) 5’. TGG AAA GAC ATG GTC CTG GGA . .3’ 
* 
Leu-110 (mutant) 5’................... CTG . . . . . . . . . . . . . . . . ...3’ 
(Leu) 
Mutagenic primer 3’-C TTT CTG GAC CAG GAC C-5’ 
217 
Ile Ile Thr His Asp Leu Glu 
His-217 (wild type) 5’. ATT ATC ACC CAT GAC CTA GAG .3’ 
* 
Leu-217 (mutant) 5’. . . . . . . . . . . . .CTT.. .3’ 
(Leu) 
Mutagenic primer 3 ‘-A TAG TGG GAA CTG GAT C-5 ’ 
a The DNA sequence of wild type D-amino acid oxidase cDNA was changed 
at the positions marked by asterisks to yield the desired mutant cDNAs 
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dehydrogenase, 0.2% Triton X-100,50 ,uM NADH, 37 mM D- 
alanine, a half of the total translate in the reticulocyte lysate 
and 50 mM sodium pyrophosphate buffer (pH 8.3) in a total 
volume of 540 pl. The reaction temperature was 25°C. 
2.7. Purification of porcine kidney DA0 
Porcine kidney DAO, purified by the method of Kubo et al. 
[13], was further purified by chromatography on hydroxy- 
apatite cellulose [14] and DEAE-Sephadex [15] columns. 
3. RESULTS AND DISCUSSION 
Since chemical modifications of Tyr-55, 
Met-110 and His-217 of porcine DA0 have been 
reported to lead to abolishment or extensive inac- 
tivation of the enzyme activity [l-4], we attempted 
to construct three mutant DAOs possessing 
Phe-55, Leu-110 or Leu-217. For this purpose, 
DA0 cDNA was subjected to oligonucleotide- 
directed mutagenesis using synthetic 17-mer 
oligonucleotides (table 1) as mutagenic primers. 
Each of the 17-mer oligonucleotides was designed 
to cause a single base substitution. That the desired 
point mutations had actually taken place was 
verified by nucleotide sequencing, which also con- 
firmed that the three point mutants were free from 
contamination by the wild type cDNA. 
The mutant cDNAs, cut out of the phage vector, 
were so ligated into pSP64 that the cDNAs were 
located downstream from the SP6 promoter. After 
linearization, the recombinant plasmids were 
transcribed with SP6 RNA polymerase and the 
transcripts were capped with guanylyltransferase. 
The capped RNAs were then translated in a rabbit 
reticulocyte lysate system. The proteins thus syn- 
thesized were analyzed by Western blot analysis. 
As shown in fig. 1, polyclonal anti-porcine DA0 
serum recognized all the three mutant DAOs (lanes 
l-3), wild type DA0 synthesized in vitro (lane 4) 
and DA0 purified from porcine kidney (lanes 
6-9). The electrophoretic mobilities of the mutant 
DAOs were the same as that of the wild type en- 
zyme (MT 38000). Densitometric omparison of the 
intensities of mutant DA0 bands (lanes l-3) with 
those of authentic wild type DA0 bands of known 
amounts (lanes 6-9) indicated that about 100 ng 
each of the mutant proteins was produced from 
5 pg each of the capped transcripts. This transla- 
tion efficiency was similar to that of wild type 
DAO. 
When the catalytic activities of the mutant 
DAOs synthesized in vitro were measured with D- 
123456789 
Mr ~10-~ 
Fig. 1. Western blot analysis of the in vitro translated wild type 
and mutant D-amino acid oxidases. Lanes: 1, Phe-55 mutant; 
2, Leu-110 mutant; 3, Leu-217 mutant; 4, wild type DAO; 5-9, 
the purified porcine kidney DA0 (5, 0 ng; 6, 5 ng; 7, 25 ng; 8, 
SO ng; 9, 100 ng). 
alanine as substrate, they all showed significant ac- 
tivities, which were strongly inhibited by benzoate, 
a potent competitive inhibitor of DA0 (fig.2). Ad- 
dition of D-alanine to the reticulocyte lysate did 
not cause any decrease in the absorbance at 
340 nm. As shown in table 2, the specific DA0 ac- 
tivities of the wild type and mutant enzymes syn- 
thesized in vitro were somewhat variable from one 
i 
10 min 
Fig.2. The enzyme reaction of the mutant DAOs and inhibition 
by benzoate. The time course of D-alanine oxidizing activity 
was monitored by means of a lactate dehydrogenase coupled 
assay as described in section 2. D-Alanine (final concentration, 
37 mM) was added at the points indicated by the first arrows 
and sodium benzoate (2 mM) was added at the points indicated 
by the second arrows. 
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Table 2 
The specific activities of the mutant DAOs 
Specific activity 
&mol D-alanine oxidized/min 
per mg protein) 
Expt 1 
Expt 2 
Wild type Phe-55 Leu-110 Leu-217 
9.0 5.5 16.0 3.3 
14.0 8.0 12.0 9.6 
experiment to another, probably because of the 
very low amount of proteins synthesized in the in 
vitro system. Inaccuracy associated with den- 
sitometric determination of DA0 proteins may 
also be responsible for the fluctuation of data. In 
any case, the specific activities of the mutant en- 
zymes were similar to one another and comparable 
with those of the wild type enzyme synthesized in 
vitro and purified porcine kidney DA0 [16]. 
From the results described above, it is clear that 
substitution of Tyr-55 with Phe, Met-l 10 with Leu 
or His-217 with Leu in porcine DA0 does not af- 
fect the catalytic activity significantly, even though 
previous chemical modification studies have sug- 
gested the importance of these three amino acid 
residues in the catalytic mechanism [l-4]. Tyr-55 
has been postulated to play a role in substrate 
binding through an ion pair with the a-amino 
group of D-amino acid [2,17]. If this is so, then 
replacement of this residue by Phe having a non- 
polar side chain would result in defective substrate 
binding and thus lead to a severe impairment of the 
catalytic activity. The finding that mutant DA0 
possessing Phe-55 is fully active indicates that this 
postulate is not tenable. A reaction mechanism in- 
volving Met-l 10 has also been proposed, in which 
it is thought to participate in the breakdown of the 
substrate-N5 flavin adduct to yield a sulfonium salt 
[4]. Further, His-217 has been suggested to take 
part directly in the catalysis by facilitating proton 
transfer or stabilizing the local conformation of 
the active center through hydrogen bonding [3]. 
Since substitution of Met-l 10 or His-217 with Leu 
has no effect on the enzyme activity, these sugges- 
tions have also to be reconsidered. It is to be noted 
in this connection that in human DA0 the 110 
position is occupied by Thr instead of Met [18]. 
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